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Abstract
Background: The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) is required for pro-inflammatory effects
of TNFα. Our previous studies demonstrated that PARP-1 mediates TNFα-induced NF-κB activation in glia. Here, we
evaluated the mechanisms by which TNFα activates PARP-1 and PARP-1 mediates NF-κB activation.
Methods: Primary cultures of mouse cortical astrocytes and microglia were treated with TNFα and suitable
signaling pathway modulators (pharmacological and molecular). Outcome measures included calcium imaging,
PARP-1 activation status, NF-κB transcriptional activity, DNA damage assesment and cytokine relesease profiling.
Results: TNFα induces PARP-1 activation in the absence of detectable DNA strand breaks, as measured by the
PANT assay. TNFα-induced transcriptional activation of NF-κB requires PARP-1 enzymatic activity. Enzymatic activation
of PARP-1 by TNFα was blocked in Ca2+-free medium, by Ca2+ chelation with BAPTA-AM, and by D609, an
inhibitor of phoshatidyl choline-specific phospholipase C (PC-PLC), but not by thapsigargin or by U73112, an inhibitor
of phosphatidyl inisitol-specific PLC (PI -PLC). A TNFR1 blocking antibody reduced Ca2+ influx and PARP-1 activation.
TNFα-induced PARP-1 activation was also blocked by siRNA downregulation of ERK2 and by PD98059, an inhibitor of
the MEK / ERK protein kinase cascade. Moreover, TNFα-induced NF-κB (p65) transcriptional activation was absent in
cells expressing PARP-1 that lacked ERK2 phosphorylation sites, while basal NF-κB transcriptional activation increased
in cells expressing PARP-1 with a phosphomimetic substitution at an ERK2 phophorylation site.
Conclusions: These results suggest that TNFα induces PARP-1 activation through a signaling pathway involving TNFR1,
Ca2+ influx, activation of PC-PLC, and activation of the MEK1 / ERK2 protein kinase cascade. TNFα-induced PARP-1
activation is not associated with DNA damage, but ERK2 mediated phosphorylation of PARP-1.
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Background
Tumor necrosis factor alpha (TNFα) has pro-inflammatory
effects in the nervous system and other tissues. These
effects are due in part to its ability to induce nuclear factor
kappa B (NF-κB) activation (as reviewed by [1, 2]). The
high-affinity TNFα receptors, TNFR1 and TNFR2, are both
expressed on astrocytes and microglia of the central ner-
vous system [3, 4], and TNFα binding to either of these re-
ceptors initiates signaling cascades that activate the IKK
kinase complex [1, 2, 5]. In the canonical NF-κB signaling
pathway, the IKK kinase complex phophorylates the IκB
subunit of cytosolic NF-κB complex, leading to the release
and nuclear translocation of NF-κB dimers. These NF-κB
dimers bind to κB sites in promoter regions of target genes,
including many genes encoding pro-inflammatory proteins
(as reviewed by [2, 5]). However, nuclear translocation and
DNA binding by NF-κB is not sufficient to induce gene
transcription. This requires for NF-κB to form a functional
transcription complex with other proteins. Evidence sug-
gests that poly(ADP-ribose) polymerase-1 (PARP-1) is a
key component of the NF-κB transcription complex [6–8].
PARP-1 forms branched poly(ADP) ribose (PAR) polymers
on several proteins involved in DNA repair and transcrip-
tion, including PARP-1 itself (PARP-1 automodification).
In addition, many nuclear proteins express binding sites
for these PAR polymers [9, 10]. The protein-protein inter-
actions resulting from PAR formation and PAR binding
modulate the function of several transcription factors, in-
cluding NF-κB [6, 11, 12], thus providing a link between
PARP-1 and cellular inflammatory responses. PARP-1 en-
zymatic inhibitors can suppress inflammatory responses
in microglia [11, 13–15] and other cell types [12, 13,
16–21]. However, it has also been reported that enzy-
matically inactive PARP-1 can facilitate NF-κB tran-
scriptional activation [22–24], suggesting that the anti-
inflammatory effects of PARP-1 inhibitors might occur
by a different mechanism.
The signal transduction pathway leading from TNFα
receptor activation to PARP-1 activation has not been
established. PARP-1 activation is classically induced by
DNA damage, in which PARP-1 binding to DNA
strand breaks or kinks triggers enzymatic activation
and poly(ADP-ribosyl)ation of histones and other pro-
teins associated with DNA repair [22]. PARP-1 was
recently shown to also be activated under several con-
ditions in which DNA damage is not known to occur,
including DNA transcription, DNA replication, and in
neurons, neurotrophin responses and memory con-
solidation [25–29]. Studies suggest that ERK2 activa-
tion and release of endoplasmic reticulum Ca2+ stores
are involved in DNA damage independent of PARP-1
activation in neurons [30, 31], but little is known
about this signaling pathway in inflammatory cells or
TNFα signaling.
Goals of the present study were to establish the mech-
anism by which TNFα leads to PARP-1 activation and to
determine whether inhibition of PARP-1 enzymatic activ-
ity blocks TNFα-induced transcriptional activation of NF-
κB. These studies used primary cell cultures of microglia
and astrocytes in order to avoid artifacts inherent in the
use of immortalized cell lines. Microglia are resident im-
mune cells of the central nervous system, and astrocytes
are glial cells that contribute to the inflammatory response
in brain. Results of these studies show that TNFα leads to
PARP-1 activation by a pathway independent of DNA
damage, involving phosphatidyl choline-specific phospho-
lipase C (PC-PLC), and ERK. The present study also dem-
onstrated that inhibition of this pathway and inhibition of





toxy]-1(2 h)-isoquinolinone (DPQ) and N-(6-oxo-5,6-
dihydrophenanthridin-2-yl)-N,N-dimethylacetamide (PJ34)
were obtained from Calbiochem (San Diego, CA) and Ino-
tek Pharmaceuticals (Lexington, MA), respectively. The
MAPK inhibitor 2-(2-amino-3-methoxyphenyl)-4H-1-ben-
zopyran-4-one (PD98059) was obtained from Tocris
Cookson Ltd. (Ellisville, MO). The PLC activator, 2,4,6-tri-
methyl-N-[3-(trifluoromethyl)phenyl]benzenesul fonamide
(m-3M3FBS) and PLC inhibitors, 1-[6-((17β-3-methoxyes-
tra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione
(U-73112) and tricyclodecane-9-yl-xanthogenate (D609)
were obtained from Calbiochem. Cell culture reagents were
obtained from Cellgro/Mediatech (Herndon,VI), and all
other reagents were from Sigma-Aldrich (St. Louis, MO)
except where otherwise stated.
Cell cultures
All animal studies were approved by the San Francisco
Veterans Affairs Medical Center animal studies commit-
tee and University of Manitoba animal care and use com-
mittee, and follow the NIH guidelines for humane care of
animals. Cultures were prepared from PARP-1−/−, and
wild-type (wt) mice as described previously [14]. The
PARP-1−/− mice were descendants of the 129S-
AdprtltmlZqw strain, originally developed by Wang et al.
[32] and obtained from the Jackson Laboratory (Bar Har-
bor, ME). These mice were outbred for seven generations
with wt CD-1 mice, and wt CD-1 mice were used as
controls for the PARP-1−/− mice. Astrocyte cultures
were prepared from 1-day old mouse pups of both
sexes in 24-well plates as described previously [33]. At
confluency, microglia were harvested by gently shaking
and re-plated at density of 5 × 105 cells/well on a 24-well
plate [14]. The microglia cultures were subsequently
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maintained in glia-conditioned medium. The confluent
astrocyte cultures were treated with 22 μM cytosine β-D-
arabinofuranoside for 2 days to inhibit the proliferation of
remaining microglia. The astrocyte cultures were subse-
quently maintained in Eagle’s minimal essential medium
(MEM) supplemented with 3 % fetal bovine serum (FBS).
Drug incubations
Studies using astrocyte cultures were initiated by re-
placing the culture medium with a physiologically bal-
anced salt solution (BSS) containing 3.1 mM KCl, 134 mM
NaCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 0.5 mM KH2PO4,
15.7 mM NaHCO3, and 2 mM glucose, pre-equilibrated to
pH 7.2 in a 5 % CO2 atmosphere. Drugs were prepared as
concentrated stock solutions in BSS. Experiments were
performed at 37 °C in a 5 % CO2 atmosphere and were ter-
minated by complete medium exchange and replacement
with fresh BSS. Studies with microglial cultures were per-
formed identically but used MEM rather than BSS.
Immunostaining
Fixation and immunostaining of cell cultures was per-
formed as previously described [14]. For detection of
poly(ADP-ribose), incubations were performed with a
1:1000 dilution of rabbit anti-poly(ADP-ribose) (Trevigen,
Gaithersburg, MD, Cat# 4336-BPC) at 4 °C for 24 h,
followed by incubation with Alexa Fluor 594-conjugated
anti-rabbit IgG (Molecular Probes, Eugene, OR), 1:500 di-
lution, for 2 h at room temperature. For evaluation of NF-
κB p65 subunit translocation, incubations were performed
with a 1:30 dilution of rabbit polyclonal anti- p65 (Cell
Signaling Technology, Inc., Danvers, MA, Cat# 3987)
at 4 °C for 24 h, followed by incubation with Alexa Fluor
594-conjugated anti-rabbit IgG (Molecular Probes, Eugene,
OR), 1:500 dilution for 2 h. In some studies, the cells were
subsequently incubated with 2 μg/ml propidium iodide for
5 min to obtain nuclear counterstaining. Confocal photomi-
crographs of astrocytes were obtained with a Zeiss LSM
510 META with a dual-PMT detector and a 32-channel
META detector and Zeiss AIM imaging software. Microglia
images were obtained with standard epifluorescence mi-
croscopy because these cells could not be cultured in a rest-
ing state on glass coverslips. Controls prepared in the
absence of primary antibody showed no staining under the
conditions described (not shown). DNA strand breaks were
detected by DNA-polymerase I-mediated biotin-dATP nick
translation (PANT) [34]. Cultures were permeabilized in
1 % Triton X-100 in phosphate buffered saline (PBS) for
30 min, and endogenous peroxidase was quenched with
2 % hydrogen peroxide. The cultures were then incubated
for 90 min with the PANT reaction mixture: 5 mM MgCl2,
10 mM 2-mercaptoethanol, 20 μg/ml bovine serum albu-
min, 30 μM dGTP, 30 μM dCTP, 30 μM dTTP, 1 μM dATP,
29 μM biotinylated dATP, and 40 U/ml of DNA-
polymerase I in PBS, pH 7.4. The biotinylated areas of
DNA strand breaks were visualized by subsequent incuba-
tion with streptavidin-horseradish peroxidase and DAB per-
oxidase substrate. Controls incubated with PANT reaction
mixture without DNA-polymerase I showed no staining.
siRNA downregulation of ERK1/2
Astrocytes were incubated with siRNA transfection com-
plexes at day 10 in vitro, at which time they are 95 % con-
fluent. siRNA incubations were performed with RNAiFect
reagents (Qiagen Inc., CA) according to the manufac-
turer’s instructions and as previously described [35]. The
culture medium of each well was replaced with 400 μl of
transfection complex mixture containing 1 μg of ERK1
siRNA or 3 μg of ERK2 siRNA and 6 μl of RNAiFect in
optiMEM. The siRNA sense sequence for ERK1 was 5′
ACAAGCGCAUCACAGUAGAtt 3′ and for ERK2 was 5′
CAAAGUUCGAGUUGCUAUCtt 3′ (Ambion Inc, TX,
USA). Controls were prepared with 3 μg of a mismatch se-
quence lacking significant homology to any known mouse
gene sequences. The siRNA complexes were removed
after 6 h and replaced with culture medium. Four days
later when cultures were used for experiments, the per-
centage of siRNA-induced reduction in ERK1 and ERK2
expressions was determined by quantitating the ERK band
size in ERK siRNA vs. mismatch siRNA transfected cul-
tures in both ctrl and TNFα conditions.
Lentivirus NF-κB reporter gene transfection
The lentivirus NF-κB reporter gene construct (pLenti-
kB-dEGFP) has a destabilized enhanced green fluores-
cent protein (dEGFP) construct under the control of five
tandem repeats of κB-enhancer elements specific for
p65and a plain TATA box [36]. Transfections were per-
formed as previously described [15]. Astrocytes were
infected with the Lenti-κB-dEGFP 4–5 days before ex-
periments. EGFP expression was evaluated 1 and 24 h
after exposure to TNFα by counting EGFP-expressing
cells from five random fields within each culture well.
TNFR1 inhibition
Cells were incubated with 100 μg/ml of TNFR1 neutralizing
antibody (anti-mouse CD120a, Affymetrix eBioscience, San
Diego, CA, Cat#16-1202) or control IgG (Armenian ham-
ster IgG, Affymetrix eBioscience, San Diego, CA, Cat#16-
4888) in MEM for 4 h prior to starting the experiments.
Calcium imaging
Intracellular calcium levels were measured in astrocytes
loaded with Fura-2-AM (Molecular Probes; 3 μM,
60 min). Experiments were carried out in bicarbonate-
free BSS at 37 °C and buffered to pH 7.2 with 10 mM
PIPES. Calcium-free BSS was prepared by omitting CaCl2
and adding 2 mM EGTA. The change in dye fluorescence
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(Fura 340/380 ratio) was measured with aZeiss 200-M
inverted microscope outfitted with an ORCA ER II micro-
scope system using Openlab Improvision software. Excita-
tion and emission wavelengths were controlled by Sutter
filterwheels and shutters. Baseline values were recorded
for 15–20 min prior to drug additions. At the end of each
experiment, the calcium ionophore A23187-Br (10 μM)
was applied to calibrate the intracellular signal. Data are
presented as a change in Fura2 emission (Fura 340/380
ratio), and as a mean change in Fura 340/380 ratio during
15-, 30-, and 60-min intervals from three to four independ-
ent experiments. In each independent experiment data
were acquired from six to ten cells at 90-s intervals, and at
10-s intervals in neutralizing antibody experiments. The
high-affinity dye, Fura-2, was used to maximize sensitivity
at low intracellular calcium concentrations, and therefore,
the signal is likely saturated and underestimates the differ-
ences between Ca2+-free and Ca2+-containing medium.
Western blotting
Western blots were prepared and quantified as described
[14]. Membranes were incubated with 1:1000 dilutions of
rabbit anti-ERK1/2 or anti phospho-ERK1/2 (Cell Signaling
Technology, Beverly, MA, Cat# 9102 and 4376), or with a
1:500 dilution of mouse monoclonal anti-poly(ADP-ribose)
(Trevigen, Gaithersburg, MD, Cat# 4335-MC). After
washing, the membranes were incubated for 2 h with
peroxidase-conjugated anti-rabbit or anti-mouse IgG (Vec-
tor Laboratories, Burlingame, CA) diluted 1:7500. The pro-
tein bands were visualized using ECLTM WB Detection kit
(Amersham-Pharmacia Biotech) and X-OMAT AR film
(Kodak) or ChemiDoc MP imaging system (BioRad). To
quantify protein loading, the membranes were re-probed
with mouse monoclonal anti β-actin at a 1:10,000 dilu-
tions, followed by peroxidase-conjugated anti-mouse IgG
(1:10,000 dilutions). Controls performed in the absence of
primary or secondary antibodies showed no signal (data
not shown). Band densities were quantified with the NIH
Image J program.
Site-directed PARP-1 mutations
The mutant PARP-1 constructs were prepared as de-
scribed [35]. In short, human PARP-1 cDNA (hPARP-1,
BC03754 from NIH Mammalian Gene Collection) was
corrected to match the human genomic sequence at
amino acid residue 762 (from alanine to valine) using Site-
Directed Mutagenesis kit (Stratagene). Single (S372E) or
double mutants (S372A and T373A) of these constructs
were then generated and sequence-verified. PARP-1−/− as-
trocytes were transfected 2 days before experiments with
the PARP-1 constructs by replacing the culture medium
with 300 μl of transfection complex mixture containing
0.5 μg of DNA and 1 μl of Lipofectamine 2000 (Invitro-
gen) in OptiMEM. The medium was replaced with culture
medium 8 h after the initiation of transfection and cells
were used for experiments 40 h later. The transfection
efficacy of this method has been established previously by
western blots detecting PARP-1 expression with a poly-
clonal antibody (ALX-210-302, Alexis/Enzo Life Sciences,
Plymounth Meeting, PA) [35].
Cytokine assay
Cytokines were analyzed in 50-μl aliquots of cell culture
medium using a Milliplex mouse multiplex immunoassay
bead system according to the manufacturer’s instructions
(Millipore) [37]. Samples were assayed in duplicate, and
the fluorescent signal corresponding to each cytokine was
measured with a BioPlex 200 system (BioRad, Hercules,
CA) in parallel with known standards. Cytokine concen-
trations measured from culture medium were normalized
to the protein content of each well as determined by the
bicinchoninic assay [38].
Statistics
For cell culture studies, each “n” denotes an independent
experiment, where each experiment is from a separate
cell culture preparation and comprised of 3–4 parallel
Fig. 1 TNFα induces PARP-1 activation in microglia and astrocytes.
Immunostaining for poly(ADP-ribose) (labeled as PAR) shows
accumulation in both astrocytes and microglia during incubation
with TNFα (15 ng/ml). Phase contrast images shows simultaneous
morphological transformation of microglia. Astrocytes do not exhibit
morphological changes (not shown). Scale bar, 10 μm. Representative
of n = 4
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treatments per condition. Results are presented as a
means ± standard error. Statistical significance was eval-
uated by one-way ANOVA followed by the Student-
Newman-Keuls multiple comparison test. p values below
0.05 were considered significant.
Results
TNFα-induced PARP-1 activation in the absence of detectable
DNA damage
TNFα at physiological concentration (15 ng/ml) induced a
rapid accumulation of PAR polymers, a product of PARP-1
enzymatic activity, in both astrocyte and microglial cultures
(Fig. 1). PAR formation in microglia was time-linked to
morphological activation, as characterized by process re-
traction and soma enlargement (Fig. 1). Astrocytes, unlike
microglia, do not undergo morphological changes in re-
sponse to TNFα (not shown). Prior studies have shown that
TNFα does not induce PAR accumulation in PARP-1−/−
cells [14], indicating that PARP-1 is the major source of
PAR formation [15, 39, 40].
PARP-1 activation is classically induced by DNA damage,
particularly DNA strand breaks [22, 41]. To determine if
DNA damage was involved in TNFα-induced PARP-1 acti-
vation, cultures were evaluated with the DNA-polymerase
I-mediated biotin-dATP nick translation (PANT) tech-
nique for single-strand DNA breaks. Cultures fixed after
1 h of TNFα incubation, a time point with robust PAR ac-
cumulation, showed no increase in PANT staining. By con-
trast, an extensive PANT signaling was observed in cells
treated with 10 μM N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG), a DNA alkylating agent widely used to induce
PARP-1 activation [42]. The degree of PARP-1 activation
induced by this concentration of MNNG was comparable
to that observed in cultures treated with TNFα (Fig. 2c).
TNFα induces PARP-1 activation through a signaling path-
way involving PLC and Ca2+
Phospholipase C (PLC) has been reported to trigger PARP-
1 activation independent of DNA damage [31]. Since PLC
can be activated by TNFα receptor stimulation [43], we
evaluated the possiblity that PLC mediates TNFα-induced
PARP-1 activation by using inhibitors to block phopha tidyl
choline-specific PLC (PC-PLC)-mediated phopha tidyl cho-
line cleavage to diacyl glycerol (DAG) (D609; 10 μM) [44]
and phosphatidyl inositol - specific PLC (PI-PLC)-me-
diated phosphatidyl inositol cleavage to IP3 (U-73112;
10 μM) [45, 46]. These studies showed that TNFα-
induced PAR formation was blocked in cultures treated
with D609, but not U-73112 (Fig. 3). Conversely, the
PLC activator m-3M3FBS [47] mimicked effects of
TNFα stimulation by inducing PARP-1 activation, NF-
Fig. 2 TNFα does not induce detectable DNA strand breaks. a PANT staining shows no detectable increase in DNA strand breaks in either microglia or
astrocyte cultures after 60-min incubation with 15 ng/ml TNFα. The DNA alkylating agent, MNNG (10 μM) is used as a positive control. Scale bar, 50 μm.
b Quantification of PANT positive cells (* p < 0.05, n= 3). c Immunostaining for PAR shows comparable PAR accumulation in cells incubated for 60 min
with 15 ng/ml TNFα or 10 μM MNNG. Scale bar, 25 μm
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κB transcriptional activation, and microglial morpho-
logical transformation, and these effects of m-3M3FBS
were likewise blocked by D609 (Fig. 4). These results
suggest that the signaling pathway linking TNFα to
PARP-1 activation involves activation of PC-PLC.
TNFα receptor activation also induces calcium influx in
astrocytes [48] and was confirmed by our studies (Fig. 5).
TNFα-induced PARP-1 activation was blocked in calcium-
free medium and by chelation of intracellular calcium with
BAPTA-AM (Fig. 3). By contrast, pre-incubation with
Fig. 3 TNFα-induced PARP-1 activation requires PLC, Ca2+ influx, and activation of MAPK-ERK kinase. a Astrocyte cultures were immunostained for
PAR after 60-min incubations with 15 ng/ml TNFα. PAR formation was prevented in calcium-free medium (containing 500 μM EGTA) and by the
calcium chelator BAPTA-AM (2 μM), but not by pre-treatment with thapsigargin (2 μM for 15 min). PAR formation was also prevented by the PC-PLC
inhibitor, D609 (10 μM), and by the MAPK-ERK inhibitor, PD98059 (10 μM). The PI-PLC inhibitor U-73112 (10 μM) did not block PAR formation. An absent
signal in cultures treated with the PARP inhibitor DPQ (25 μM) confirms the specificity of the immunostaining. Representative of n = 4. b PAR
immunostaining in microglia shows the same pattern as observed in astrocytes. Studies using EGTA were not possible with microglia cultures
due to rapid cell detachment. c Phase contrast images of same microglial files shown in b. Microglial morphological transformation induced
by TNFα is absent under the conditions in which PAR formation was blocked. Scale bars, 50 μm. d Quantification of PAR positive cells (avarage
number per field in confluent astoglia cultures; percent of positive cells in microglia cultures). (*p < 0.05, n = 3–4)
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thapsigargin to deplete endoplastic reticulum (ER) calcium
stores did not prevent either TNFα-induced intracellular
Ca2+ elevations (Fig. 5b) or PAR formation (Fig. 3).
Studies with a TNF receptor 1 (TNFR1)-neutralizing
antibody were performed to assess the role of this recep-
tor subtype in PARP-1 activation. The neutralizing anti-
body delayed and reduced TNFα-induced intracellular
Ca2+ elevations (Fig. 5a, c, d). The TNFR1 neutralizing
antibody also reduced PAR formation (Fig. 5e), suggest-
ing that TNFR1 has a critical role in PARP-1-related in-
flammatory responses.
ERK2 inhibition prevents TNFα-induced PARP-1 activation
ERK2 promotes PARP-1 activation by phosphorylating
PARP-1 [35, 49]. The MEK/ERK kinase cascade is acti-
vated PC-PLC [50], thus suggesting ERK2 as a potential
link between TNFα receptor activation and PARP-1 acti-
vation. Here, ERK1/2 phosphorylation (activation) began
within 10 min of TNFα exposure (Fig. 6a, c). Inhibition of
the ERK1/2 activation with PD98059 [51] prevented
TNFα-induced PARP-1 activation in both astrocyte and
microglia cultures (Fig. 3). siRNA reduction of ERK2 ex-
pression also prevented TNFα-induced PARP-1 activation,
whereas ERK1 silencing had no effect (Fig. 6b, c, d).
ERK2 phosphorylation of PARP-1 induces NF-κB activation
The role of ERK2-mediated phosphorylation in PARP-1
activation was further evaluated using PARP-1 constructs
containing mutations at the ERK2 phosphorylation sites,
S372 and T373 [35]. The S372A and T373A mutations
prevent ERK2-mediated phosphorylation, and S372E pro-
vides a constitutive phosphorylation mimic. PARP-1−/−
astrocyte cultures were transfected with either wt or
mutant PARP-1 constructs, and NF-κB transcriptional ac-
tivation was assessed using a lentivirus-delivery of dEGFP
reporter gene that is activated by the p65 subunit of NF-
κB [36]. In cells transfected with wt PARP-1, TNFα
induced a robust activation of the reporter gene within
1 h and a further increase at 24 h. This TNFα-induced
transcriptional activation was absent in non-transfected
Fig. 4 PLC activation triggers microglial morphologial transformation and activation of PARP and NF-κB, independent of TNFα. a The PLC activator
m-3M3FBS (25 μM, 60 min) induces microglial morphological transformation and PARP activation. The PC-PLC inhibitor, D609 (10 μM) prevents
both effects of the PLC activator. Scale bar, 10 μm. b Quantification of PAR positive cells (*p < 0.05, n = 3). c NF-κB transcriptional activity was evaluated
in cultures transfected with a reporter gene in which dEGFP expression (green) is driven by NF-κB p65 subunit binding. The PLC activator m-3M3FBS
(25 μM, 60 min) induced NF-κB activation as seen by dEGFP expression. This NF-κB transcriptional activity was blocked by both PLC inhibitor D609
(10 μM) and PARP-1 inhibitor DPQ (25 μM)
Vuong et al. Journal of Neuroinflammation  (2015) 12:229 Page 7 of 16
cells. It was also absent in transfected cells treated with
the PARP inhibitor DPQ, thus confirming a require-
ment for PARP-1 enzymatic activity in this process.
Cells transfected with the mutant PARP-1 lacking
ERK2 phosphorylation sites (S372A and T373A) also
showed no TNFα-induced NF-κB activity. By contrast,
cells transfected with the S372E PARP-1 construct,
which mimics constitutive phosphorylation by ERK2,
showed increased GFP expression in the absence of
TNFα stimulation (Fig. 7). Of note, neither PARP-1 de-
ficiency nor PARP-1 inhibition blocked the nuclear
translocation of p65 induced by TNFα (Fig. 8). We also
analyzed TNFα-induced cytokine release and saw de-
crease in NF-κB-dependent pro-inflammatory cytokines
Fig. 5 TNFα induces calcium influx via TNFα receptor 1 (TNFR1). a TNFα induced increase in intracellular free Ca2+, as indicated by the change in
Fura2 emission. This increase was blocked in Ca2+-free medium (0 Ca2+ + 0.5 mM EGTA, green), and the intracellular calcium response profile was
changed by neutralizing TNFR1 antibody (TNFR1 ab, red). IgG antibody (IgG ab, blue) was used as a control. Arrow denotes addition of TNFα
(15 ng/ml) to the astrocyte cultures. The Ca2+ ionophore, A23187-Br (10 μM) was added at the end of each experiment (arrow head) to provide a
calibration point. b TNFα-induced intracellular free Ca2+ (Fura2 ratio) increase was prevented in Ca2+-free medium but was not affected in cells
pre-treated with thapsigargin (2 μM). *p < 0.05 compared to control at each time point; #p < 0.05 compared to TNFα at each designated time
point, n = 5–6. c, d TNFR1 neutralizing antibody (TNFR1 ab) delayed calcium influx rise onset and reduced the influx plateau time, but the calcium
influx maximum of the level of intracellular free Ca2+ (Fura2 ratio) was not affected between TNFR1 ab and IgG ab-pre-treated TNFα-stimulated
cells. *p < 0.05, n = 5. e PARP-1 activation profile detected by PAR formation was also changed when TNFR1 was blocked. TNFR1 neutralizing antibody
reduced the length and level of PAR formation, mimicking effects of PARP inhibitor. *p < 0.05, n = 3
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Fig. 6 TNFα-induced PARP activation is regulated by ERK2. a TNFα (15 ng/ml) induces ERK1/2 phosphorylation in astrocyte cultures.
Representative of n = 3. b PAR immunoblots shows that TNFα-induced PAR formation is reduced after siRNA downregulation of ERK2, but not
ERK1. PAR is seen as a discrete band at 116 kDa attributable to auto-poly(ADP)-ribosylation of PARP-1 and as a smear over other molecular
weights resulting from PAR formation on other proteins. Actin band shows protein loading. ERK1 and ERK2 expression are shown below the PAR
western blot. The siRNA treatments reduced their expression by 72 ± 8 % and 72 ± 5 %, respectively, with protein loading shown by the actin
band. c Quantification of PAR western blots, conditions as in b; * p < 0.05, n = 3. d Immunostaining for PAR also shows that TNFα-induced PAR
formation is suppressed by siRNA downregulation of ERK2 expression. Images are representative of four independent experiments. All PAR formation
studies are conducted 60 min after TNFα stimuli
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Fig. 7 ERK2-mediated phosphorylation of PARP-1 induces NF-κB transcriptional activity. a NF-κB transcriptional activity was evaluated in astrocytes
transfected with a reporter gene in which dEGFP expression (green) is driven by NF-κB p65 subunit binding. TNFα-induced (15 ng/ml). dEGFP expression is
blocked by the PARP-1 inhibitor, DPQ (25 μM). Scale bar, 20 μm. Quantified data are shown in c. (*p< 0.05 compared to control, #p< 0.05 compared to
TNFα, n= 3–4). b TNFα-induced GFP expression is absent in PARP1−/− astrocytes and reconstituted in PARP-1−/− astrocytes transfected with normal human
PARP-1 (wt PARP-1) but not with mutant S372A and T372A PARP-1, which lacks ERK2 phosphorylation sites. Conversely, PARP-1−/− astrocytes transfected
with mutant S372E PARP-1, which has a phosphomimetic glutamate residue at an ERK2 phosphorylation site, show increased basal NF-κB transcriptional
activation. Scale bar, 10 μm. Quantified data are shown in d. (*p< 0.05 compared to wt PARP-1, n= 3). Expression levels of the mutant PARP-1 species were
comparable, as evaluated by PARP-1 western blots using a polyclonal antibody (not shown)
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(IFNγ, IL-1β, KC, MCP-1, MIP-1β) in both PARP-1−/−
microglia and in wt microglia upon PARP inhibition
with PJ34 (500 nM) (Table 1), providing more func-
tional outcome measure for PARP-1 mediated NF-κB
regulation. Interestingly, PARP-1 inhibition did not re-
duce anti-inflammatory cytokines (IL-4, IL-10, IL-13,
TGFβ) (Table 1).
PLC does not have a role in PARP-1 activation induced by
DNA damage
Taken together, these findings suggest a signaling pathway
in which TNFα interaction with TNFR1 triggers prolonged
Ca2+ influx, PC-PLC activation, ERK2 phosphorylation,
and activation of PARP-1. We therefore evaluated whether
this pathway is involved in PARP-1 activation induced by
DNA damage. Astrocytes were exposed to 10 μM MNNG
to induce DNA damage sufficient to produce PARP-1 acti-
vation comparable to that induced by TNFα (Fig. 2c).
DNA damage-induced PARP-1 activation, like TNFα-
induced activation, was blocked by the MEK/ERK inhibitor
PD9089; however, it was not blocked by the PLC inhibitor
D609 or by Ca2+-free medium and was only partly blocked
by BAPTA-AM (Fig. 9).
Discussion
The mechanism by which PARP-1 is activated by TNFα
and mediates TNFα pro-inflammatory effects has not
been previously established. Results of these studies sug-
gest that TNFα induces PARP-1 activation by a pathway
involving TNFR1, calcium entry, activation of PC-PLC,
and activation of the MEK1/ERK2 protein kinase cas-
cade. This signaling pathway differs in key respects from
the pathway involved in classical PARP-1 activation by
DNA damage (Fig. 10). These results also show that
PARP-1 enzymatic activity is required for TNFα-induced
NF-κB transcriptional activation and related cytokine
production in glia.
NF-κB activation involves its translocation to the nu-
cleus, transcription complex formation and binding to
DNA [2]. However, these events alone do not necessarily
Fig. 8 PARP-1 is not required for NF-κB nuclear translocation. The subcellular localization of the NF-κB p65 subunit (green) was visualized by
immunostaining in wt and PARP-1−/− astrocyte cultures after TNFα exposure. Nuclei were stained with propidium iodide (red). Cells fixed after
30 min of TNFα (15 ng/ml) exposure show overlap of these signals (yellow), indicative of p65 movement into the nucleus. This movement was
not blocked by the PARP inhibitor DPQ (25 μM) or in PARP-1−/− cells. Representative of n = 3. Scale bar, 50 μm
Table 1 Microglial cytokine and trophic factor release in vitro upon TNFα stimulation
Pro-inflammatory cytokines
IFNγ IL-1β KC MCP-1 MIP-1β
Ctrl (wt) 221.97 ± 36.69 20.4 ± 1.9 157.12 ± 20.8 103.63 ± 21.5 2840.02 ± 357.4
TNFα (wt) 335.76 ± 21.3* 59.38 ± 2.8* 408.13 ± 60.0* 668.0 ± 78.7* 4777.28 ± 527.6*
TNFα + PJ34 (wt) 284.09 ± 21.6** 35.2 ± 2.3** 197.75 ± 25.4** 339.35 ± 77.9** 3081.38 ± 353.7**
PJ34 (wt) 68.48 ± 16.6* 1.35 ± 2.0* 24.67 ± 11.1* 153.96 ± 33.4 1664.42 ± 361.8*
Ctrl (PARP-1−/−) 101.03 ± 21.2* 13.82 ± 4.0* 22.30 ± 6.7* 46.84 ± 16.7* 1104.99 ± 172.0*
TNFα (PARP-1−/−) 101.97 ± 17.9** 14.12 ± 3.0** 67.07 ± 18.9** 84.10 ± 28.7** 1118.34 ± 146.1**
Anti-inflammatory cytokines and trophic factors
IL-4 IL-10 IL-13 TGF-β VEGF
Ctrl (wt) 0.8 ± 0.5 21.1 ± 1.2 1.03 ± 0.1 1.11 ± 0.2 4.280 ± 1.2
TNFα (wt) 1.46 ± 0.5 22.78 ± 10.9 0.2 ± 0.3* 1.35 ± 0.2 2.82 ± 0.6
TNFα + PJ34 (wt) 6.09 ± 0.8* 34.77 ± 8.3* 25.00 ± 4.8** 1.41 ± 0.1 39.57 ± 6.6**
PJ34 (wt) 1.48 ± 0.4 19.0 ± 1.3 0.89 ± 0.2 1.31 ± 0.1* 22.92 ± 3.7*
Ctrl (PARP-1−/−) 0.77 ± 0.1 7.47 ± 11.3 5.73 ± 1.1* 1.37 ± 0.1* 13.63 ± 5.3*
TNFα (PARP-1−/−) 0.86 ± 0.4 11.16 ± 1.9 2.69 ± 0.5** 1.90 ± 0.2** 21.98 ± 4.7**
Data is presented as a pg of cytokine detected from the cell culture medium, normalized to mg of protein in corresponding cell culture well (mean ± stdev). PJ34
is a PARP-1 inhibitor. *p ≤ 0.05 compared to ctrl (wt), **p ≤ 0.05 compared to TNFα (wt), n = 3–4
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result in NF-κB-driven gene transcription; transcription of
the target gene can be prevented by parallel binding of
repressors or other contradicting processes [12, 52, 53].
Results presented here with an NF-κB reporter gene assay
provide an example of this; PARP-1 inhibitors allowed NF-
κB translocation to the nuclei, but blocked NF-κB-
mediated gene transcription of pro-inflammatory cytokine,
while some anti-inflammatory cytokines (IL-10, IL-13),
which have a κB site in their promoter [54, 55] were not
reduced by PARP-1 ablation. The reporter gene approach
also clarifies the importance of PARP-1 enzymatic activity
in NF-κB activation. Several reports indicate that PARP-1
inhibitors can block glial inflammatory responses and the
associated upregulation of proteins with NF-κB promotor
sites [11, 13–15, 18, 56], but other reports suggest that
PARP-1 enzymatic activity is not required for NF-κB tran-
scriptional activation [24]. The present results demonstrate
that PARP-1 enzymatic activity is required for transcrip-
tional activity induced by the p65 subunit of NF-κB in as-
trocytes. However, we cannot exclude a non-enzymatic
interaction between PARP-1 and other NF-κB DNA-
binding subunits or in non-canonical NF-κB activation
[57]. Both genetic depletion and pharmacologic inhibition
of PARP-1 were found to inhibit NF-κB-dependent pro-
inflammatory cytokines, but interestingly, anti-inflammatory
cytokines were not inhibited. This suggests that immune
modulation ability of PARP-1 [37] is a result of complex
transcriptional regulation, possibly involving other tran-
scription factors [58].
Although PARP-1 activation is classically associated with
DNA damage, in which PARP-1 binding to DNA strand
breaks or kinks triggers its enzymatic activation, PARP-1
activation also occurs in settings such as gene transcription
and neurotrophin signaling, in which DNA damage is not
known to occur [25–31]. PARP-1 activation induced by
TNFα would similarly be expected to occur independent of
DNA damage, but it is also possible that TNFα could up-
regulate pro-oxidant inflammatory responses and thereby
lead to DNA damage [59]. This possibility was ex-
cluded here using the PANT assay, which showed no
Fig. 9 PLC is not required for DNA damage-induced PARP-1 activation. a Astrocytes were immunostaining for PAR (green) and nuclei were
counterstained with propidium iodide (red). PAR formation induced by MNNG (10 μM, 60 min) was prevented by inhibitors of PARP (DPQ; 25 μM) and
MEK-ERK1/2 (PD98059; 10 μM), but not by PC-PLC inhibitor (D609; 10 μM) or by calcium-free medium (500 μM EGTA). Intracellular calcium chelation
with BAPTA-AM (2 μM) produced a partial reduction in PAR formation. Scale bar, 40 μm. b Quantification of PAR positive cells (#p < 0.05 compared to
control, *p < 0.05 compared to MNNG alone, n = 3)
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increase in single-strand DNA breaks in cultures incubated
with TNFα.
Our results indicate some commonalities in the signal
transduction pathways mediating DNA damage-induced
PARP-1 activation and TNFα-induced PARP-1 activation.
PARP-1 activation induced by DNA damage requires
PARP-1 to be phosphorylated at an ERK2 phosphorylation
site [35]. Here, PARP-1 activation induced by TNFα was
found to be blocked by siRNA downregulation of ERK2
expression and by PD98059, which inhibits ERK2 activa-
tion. In addition, cells expressing mutant PARP-1 that lack
the ERK2 phosphorylation at sites S372 and T373 showed
no PARP-1 activation [35] and no NF-κB transcriptional
activation, whereas cells expressing mutant PARP-1 con-
taining the phosphomimetic S372E mutation showed an
increase in both basal PARP-1 activity and basal NF-κB
transcriptional activity. These findings suggest that ERK2
phosphorylation of PARP-1 at S372 and/or T373 is re-
quired for PARP-1 activation triggered by either DNA dam-
age or by TNFα. We cannot exclude the possibility that
other mitogen-activated protein kinases (MAPKs) have a
role in TNFα-induced PARP-1 activation. TNFα certainly
stimulates phosphorylation of p38 MAPK and cJun N-
terminal kinase (JNK) [60], which could at least indirectly
facilitate PARP-1 activation or parallel processes. Indeed,
activation of JNK is a required downstream event in PARP-
1-mediated (MNNG-induced) necrotic cell death [61, 62],
and p38 interaction with PARP-1 is a crucial step in hydro-
gen peroxide-induced cell death pathway [63]. Notably,
phosphorylation of both of these MAPKs were identified
downstream of PARP-1 activation. Our previous studies
assessed the role of p38, JNK, and ERK1/2 in MNNG-
induced PARP-1 activation and cell death, and only ERK1/2
inhibition reduced both [35].
Our results also indicate differences in the DNA
damage-induced and TNFα-induced PARP-1 activation
pathways. PARP-1 activation by MNNG, a DNA alkylat-
ing agent, was not inhibited by the PC-PLC inhibitor
D609 or by Ca2+-free medium and only partially inhib-
ited by the intracellular Ca2+ chelator BAPTA-AM. By
contrast, TNFα-induced PARP-1 activation was com-
pletely blocked by D609, Ca2+-free medium, and
BAPTA-AM. The Ca2+i increase induced by TNFα was
abrogated by Ca2+-free medium but not by thapsigargin
pre-treatment, suggesting that the increased Ca2+i origi-
nates from the extracellular space rather than the ER.
Fig. 10 The schematic summary of TNFα-induced PARP-1 activation pathway in glial cells. PARP-1 activation induced by TNFα does not involve
DNA damage, which is a classical inducer of PARP-1 activation. A MNNG-induced DNA damage activation pathway differs from a TNFα-induced
one, but they both share the requirement of ERK2-mediated PARP-1 phosphorylation. TNFα binding to its receptor TNFR1 induces calcium influx,
and activates phosphotidyl choline-specific phospholipase (PC-PLC) leading to phosphotidyl choline cleavage to diacyl glycerol (DAG). This
process leads to activation of mitogen-activated protein kinase pathway (MEK1/2-ERK1/2) and ERK2-mediated phosphorylation of PARP-1, which
allow PARP-1 activation. Enzymatically active PARP-1 co-activates NF-κB transcriptional activation promoting pro-inflammatory secretion profile.
TNFα-induced PARP-1 activation was prevented by calcium chelators (EGTA, BAPTA-AM), TNFR1-neutralizing antibody (ab), inhibitors of PC-PLC-
DAG (D609), MEK1/2-ERK1/2 (PD98059), PARP (DPQ) and ERK2 siRNA, while MNNG-induced PARP activation was affected only by inhibitors of
ERK2 and PARP. TNFα-induced NF-κB transcription activation was prevented by inhibitors of PC-PLC-DAG, ERK1/2 and PARP
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Also arguing against a role for ER calcium release was the
finding that TNFα-induced PARP-1 activation was not
blocked by U73112, an inhibitor of PI-PLC-induced IP3
formation, but was inhibited by D609, which inhibits PC-
PLC-induced DAG formation. Similarly, neutralizing anti-
body against TNFR1, extracellular receptor for TNFα, sig-
nificantly diminished the TNFα-induced increase in Ca2+i
and PAR formation. Moreover, the PLC-activating com-
pound m-3M3FBS induced PARP-1 activation and NF-κB
transcription activity, which were prevented by inhibitor
targeting PLC-DAG signaling in the absence of other
stimuli, suggesting that this pathway is sufficient to induce
PARP-1 activity independent of DNA damage. These find-
ings are congruent with prior work; TNFα binding to its
TNFR1 receptor can stimulate PC-PLC activation and
production of DAG (as reviewed by [50]. DAG precedes
PKC activation, which in turn activates the MEK/ERK
protein kinase cascade in astocytes [64]. In macrophage
cultures, LPS-induced activation was reported to involve
PC-PLC, DAG, PKCζ, and ERK1/2 [65]. While PKCs are
likely mediators between DAG and MEK/ERK activation
also in the signaling pathway described in our present re-
port, further studies are required to identify whether they
have a role in PARP-1 activation and which subunits are
involved. The potential route for calcium influx could be
through store-operated channels (SOCs), which are
known to be regulated by TNFα-induced K+ current upon
TNFα stimulation in human microglia [66]. PLC-DAG ac-
tivation has also been reported to trigger opening of SOCs
[67, 68].
Our data demonstrate the critical role of TNFR1 in
PARP-1-related inflammatory responses, which is fitting as
TNFR1 is a dominant pro-inflammatory receptor expressed
by microglia and also associated with NF-κB-dependent
anti-apoptotic transcriptional activity [69]. However, we
cannot completely exclude the role of TNFR2, as the data
relies on specificity of TNFR1 antibody, and there is no
commercially available neutralizing antibody for TNFR2.
It also remains to be established how the described signal-
ing components (i.e., PC-PLC, calcium influx, and ERK2)
upon TNFR1 stimulation interact with the classical TNFR
adaptor proteins sucs as TRADD, TRAF-2, and RIP1.
A key role for ERK2 in DNA damage-independent
PARP-1 activation has been previously attributed to a
non-enzymatic interaction between ERK2 and PARP-1
[30, 31]. Prior studies have also suggested a role for PLC-
mediated liberation of IP3 and ER calcium from within the
nucleus itself as a factor stimulating PARP-1 activity [31].
The present findings do not address this possibility dir-
ectly, but the failure of thapsigargin or D609 to block
PARP-1 activation, along with the suppression of PARP-1
activation in Ca2+-free medium, argues against ER Ca2+
release as a major factor in the setting of TNFα stimulation.
Whether these experimental differences are attributable to
cell-type differences, differing cell stimuli, or other factors
remains to be established.
PARP-1 is by far the most abundant and active PARP
species in the cell nucleus, but PARP-2 and PARP-3 are
also present [40, 70, 71]. Recent findings have identified
distinct roles for PARP-2 and PARP-3 in the astrocyte
inflammatory responses induced by S. Aureus [72]. A
major contribution of PARP-2 or PARP-3 to the PAR
formation and NF-κB activation observed in the present
studies is unlikely because no PAR formation or NF-κB
activation was observed in PARP-1 deficient cells. How-
ever, the differing PARP species interact [73, 74]. It is
therefore possible that the different PARP species and
interactions between these species may have signal-
specific effects on transcription factor activities.
Conclusions
TNFα stimulation of glial cells leads to PARP-1 activation
via a mechanism that is independent of DNA strand
breaks. TNFα stimulates PARP-1 activation by a pathway
involving TNFR1, calcium entry, activation of PC-PLC,
and activation of the MEK1/ERK2 protein kinase cascade.
PARP-1 enzymatic activity is required for TNFα-induced
NF-κB transcriptional activation and pro-inflammatory
cytokine release.
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